北京三家综合医院抗高血压用药方案组成及主要治疗患者分析

doi:10.5246/jcps.2013.04.054

北京三家综合医院抗高血压用药方案组成及主要治疗患者分析

郑凯, 孙迎琪, 魏艳红, 杨巍, 孔维华, 邵宏^*, 王天晟

1. 北京大学医学部药学院药事管理与临床药学系, 北京 100191
2. 国家知识产权局专利审查协作中心, 北京 100190

收稿日期:2013-01-05 修回日期:2013-03-11 出版日期:2013-07-10 发布日期:2013-07-10
通讯作者: 邵宏*

Analysis of antihypertensive regimens and their intended patients from
three hospitals in Beijing

Kai Zheng, Yingqi Sun, Yanhong Wei, Wei Yang, Weihua Kong, Hong Shao^*, Tiansheng Wang

1. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. Patent Examination Cooperation Center of State Intellectual Property Office of China, Beijing 100190, China

Received:2013-01-05 Revised:2013-03-11 Online:2013-07-10 Published:2013-07-10
Contact: Hong Shao*

摘要/Abstract

摘要：

本研究旨在调查不同抗高血压药物如何组成治疗方案及其治疗结果。我们在北京三家医院回顾性收集了974张用于治疗高血压的处方, 并从其中一家医院收集了219份病历以研究不同类型的高血压用药方案及患者之间的关系。抗高血压用药方案按照其中降压药的亚类组合分类。几乎所有的处方均可被分到11组抗高血压用药方案, 其中大部分为多药联合治疗。包含CCB类和RAAS抑制剂 (ARB或ACEI)的治疗方案较其他方案显著倾向于治疗高血压III级患者(P<0.001)。β受体阻滞剂的方案中最常与CCB组成联合治疗方案。氢氯噻嗪的使用不及指南推荐的广泛。

关键词: 抗高血压药物, 用药方案组成, 对应患者, 高血压

Abstract:

This study aimed to investigate various regimens of antihypertensive agents for different groups of patients and the outcomes in the real world. We retrospectively collected 974 prescriptions for hypertension from three hospitals in Beijing, along with medical records of 219 hypertensive patients from one of the hospitals to study the regimens and their effects on patients. The antihypertensive regimens were classified by different combinations of subclasses of antihypertensive agents. Nearly all prescriptions can be classified into 11 different antihypertensive regimens, and most of them are combination therapy. Grade III hypertension patients significantly (P<0.001) tend to be treated with regimens containing calcium channel blocker (CCB) and RAAS inhibitors, angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI). β-Blockers are more likely to be combined with CCB than with other categories of antihypertensive agents. Hydrochlorothiazide is less widely used than recommended.

Key words: Antihypertensive agents, Combination, Intended patients, Hypertension

中图分类号:

R969.4

Supporting:

^*Corresponding author. Tel.: 86-10-82805020

郑凯, 孙迎琪, 魏艳红, 杨巍, 孔维华, 邵宏^*, 王天晟. 北京三家综合医院抗高血压用药方案组成及主要治疗患者分析[J]. , DOI: 10.5246/jcps.2013.04.054.

Kai Zheng, Yingqi Sun, Yanhong Wei, Wei Yang, Weihua Kong, Hong Shao^*, Tiansheng Wang. Analysis of antihypertensive regimens and their intended patients from
three hospitals in Beijing[J]. , DOI: 10.5246/jcps.2013.04.054.

参考文献

[1] Hu, D.Y.; Liu, L.S.; Yu, J.M.; Yao, C.H. Chin. J. Cardiol. 2010, 38, 230-238.
[2] Mancia, G.; Laurent, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Burnier, M.; Caulfield, M.J.; Cifkova, R.; Clement, D.; Coca, A.; Dominiczak, A.; Erdine, S.; Fagard, R.; Farsang, C.; Grassi, G.; Haller, H.; Heagerty, A.; Kjeldsen, S.E.; Kiowski, W.; Mallion, J.M.; Manolis, A.; Narkiewicz, K.; Nilsson, P.; Olsen, M.H.; Rahn, K.H.; Redon, J.; Rodicio, J.; Ruilope, L.; Schmieder, R.E.; Struijker-Boudier, H.A.; Van Zwieten, P.A.; Viigimaa, M.; Zanchetti, A. Blood Press. 2009, 18, 308-347.
[3] Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, A.M.; Kjeldsen, S.E.; Laurent, S.; Narkiewicz, K.; Ruilope, L.; Rynkiewicz, A.; Schmieder, R.E.; Boudier, H.A.; Zanchetti, A. J. Hypertens. 2007, 25, 1751-1762.
[4] Parati, G. J. Cardiovasc. Pharmacol. 2009, 53, 352-358.
[5] Chrysant, S.G. Am. J. Cardiovasc. Drugs. 2010, 10, 315-320.
[6] Mourad, J.J.; Le Jeune, S.; Pirollo, A.; Mourad, C.; Gaudouen, Y.; Lopez-Sublet, M. Curr. Med. Res. Opin. 2010, 26, 2263-2276.
[7] de la Sierra, A. J. Hum. Hypertens. 2009, 23, 503-511.
[8] Hasebe, N.; Kikuchi, K. J. Hypertens. 2005, 23, 445-453.
[9] Neutel, J.M.; Smith, D.H.G.; Weber, M.A.; Schofield, L.; Purkayastha, D.; Gatlin, M. J. Clin. Hypertens. 2005, 7, 641-646.
[10] Boutouyrie, P.; Achouba, A.; Trunet, P.; Laurent, S. Hypertension. 2010, 55, 1314-1322.
[11] Matsui, Y.; Eguchi, K.; O'Rourke, M.F.; Ishikawa, J.; Miyashita, H.; Shimada, K.; Kario, K. Hypertension. 2009, 54, 716-723.
[12] Jamerson, K.; Weber, M.A.; Bakris, G.L.; Dahlof, B.; Pitt, B.; Shi, V.; Hester, A.; Gupte, J.; Gatlin, M.; Velazquez, E.J. N. Engl. J. Med. 2008, 359, 2417-2428.
[13] Dahlof, B.; Sever, P.S.; Poulter, N.R.; Wedel, H.; Beevers, D.G.; Caulfield, M.; Collins, R.; Kjeldsen, S.E.; Kristinsson, A.; McInnes, G.T.; Mehlsen, J.; Nieminen, M.; O'Brien, E.; Ostergren, J. Lancet. 2005, 366, 895-906.
[14] Kjeldsen, S.E.; Weber, M.; Oparil, S.; Jamerson, K.A. Blood Press. 2008, 17, 260-269.
[15] Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, A.M.; Kjeldsen, S.E.; Laurent, S.; Narkiewicz, K.; Ruilope, L.; Rynkiewicz, A.; Schmieder, R.E.; Boudier, H.A.; Zanchetti, A.; Vahanian, A.; Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Filippatos, G.; Funck-Brentano, C.; Hellemans, I.; Kristensen, S.D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L.; Erdine, S.; Kiowski, W.; Agabiti-Rosei, E.; Ambrosioni, E.; Lindholm, L.H.; Viigimaa, M.; Adamopoulos, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Bertomeu, V.; Clement, D.; Erdine, S.; Farsang, C.; Gaita, D.; Lip, G.; Mallion, J.M.; Manolis, A.J.; Nilsson, P.M.; O'Brien, E.; Ponikowski, P.; Redon, J.; Ruschitzka, F.; Tamargo, J.; van Zwieten, P.; Waeber, B.; Williams, B. J. Hypertens. 2007, 25, 1105-1187.
[16] Bisognano, J.D.; McLaughlin, T.; Roberts, C.S.; Tang, S.S. Vasc. Health Risk Manag. 2007, 3, 579-585.
[17] Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.J.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.J.; Roccella, E.J. Hypertension. 2003, 42, 1206-1252.
[18] Bartholow, M. Pharm. Times. 2010, 35-36. This article can be found online at http://www.pharmacytimes.com/publications/issue/2010/May2010/RxFocusTopDrugs-0510
[19] Garber, A.J.; Handelsman, Y.; Einhorn, D.; Bergman, D.A.; Bloomgarden, Z.T.; Fonseca, V.; Garvey, W.T.; Gavin III, J.R.; Grunberger, G.; Horton, E.S.; Jellinger, P.S.; Jones, K.L.; Lebovitz, H.; Levy, P.; McGuire, D.K.; Moghissi, E.S.; Nesto, R.W. Endocr. Pract. 2008, 14, 933-946.
[20] de Galan, B.E.; Perkovic, V.; Ninomiya, T.; Pillai, A.; Patel, A.; Cass, A.; Neal, B.; Poulter, N.; Harrap, S.; Mogensen, C.E.; Cooper, M.; Marre, M.; Williams, B.; Hamet, P.; Mancia, G.; Woodward, M.; Glasziou, P.; Grobbee, D.E.; MacMahon, S.; Chalmers, J. J. Am. Soc. Nephrol. 2009, 20, 883-892.
[21] Atkins, R.C.; Briganti, E.M.; Lewis, J.B.; Hunsicker, L.G.; Braden, G.; Champion, D.C.P.; DeFerrari, G.; Drury, P.; Locatelli, F.; Wiegmann, T.B.; Lewis, E.J. Am. J. Kidney Dis. 2005, 45, 281-287.
[22] Zhu, K.C.; Cao, G.Y.; Hu, X. J. Chin. Pharm. Sci. 2012, 21, 205-210.
[23] Karnes, J.H.; Cooper-DeHoff, R.M. Expert Rev. Cardiovasc. Ther. 2009, 7, 689-702.
[24] Elliott, W.J.; Meyer, P.M. Lancet. 2007, 369, 201-207.
[25] Kuzmanic, D.; Laganovic, M.; Dika, Z.; Kos, J.; Pecin, I. Lijec. Vjesn. 2006, 128, 336-341.
[26] Torp-Pedersen, C.; Metra, M.; Charlesworth, A.; Spark, P.; Lukas, M.A.; Poole-Wilson, P.A.; Swedberg, K.; Cleland, J.G.; Di Lenarda, A.; Remme, W.J.; Scherhag, A. Heart. 2007, 93, 968-973.
[27] Mcgill, J.B.; Bakris, G.L.; Fonseca, V.; Raskin, P.; Messerli, F.H.; Phillips, R.A.; Katholi, R.E.; Wright Jr., J.T.; Iyengar, M.; Anderson, K.M.; Lukas, M.A.; Dalal, M.R.; Bell, S.H. Diabetes Obes. Metab. 2007, 9, 408-417.
[28] Phillips, R.A.; Fonseca, V.; Katholi, R.E.; McGill, J.B.; Messerli, F.H.; Bell, D.S.; Raskin, P.; Wright, J.J.; Iyengar, M.; Anderson, K.M.; Lukas, M.A.; Bakris, G.L. J. Cardiometab. Syndr. 2008, 3, 211-217.
[29] Bell, D.S.; Bakris, G.L.; McGill, J.B. Diabetes Obes. Metab. 2009, 11, 234-238.